JPMorgan Chase & Co. Has $10.68 Million Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• JPMorgan cut its stake: JPMorgan Chase reduced its position in LeMaitre Vascular by 18.6% to 121,988 shares worth about $10.68 million, while institutional investors now own roughly 84.6% of the stock.
• Strong quarter and guidance: LeMaitre beat Q4 estimates with $0.68 EPS and $64.45 million revenue (up 15.7% YoY), set FY2026 EPS guidance of $2.81–3.01 and raised its quarterly dividend to $0.25 ($1.00 annual).
• Significant insider selling: Insiders have sold 215,438 shares (~$23.1 million) in the last 90 days, including CEO George W. LeMaitre’s sale of 55,930 shares for about $6.03 million, though insiders still own 9.5% of the company.

JPMorgan Chase & Co. cut its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 18.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 121,988 shares of the medical instruments supplier's stock after selling 27,800 shares during the quarter. JPMorgan Chase & Co. owned 0.54% of LeMaitre Vascular worth $10,675,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in LMAT. Tudor Investment Corp ET AL acquired a new stake in LeMaitre Vascular in the third quarter valued at approximately $6,056,000. CIBC Bancorp USA Inc. acquired a new position in shares of LeMaitre Vascular during the third quarter worth $799,000. Advisory Services Network LLC bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $98,000. PharVision Advisers LLC bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $355,000. Finally, Verition Fund Management LLC boosted its holdings in shares of LeMaitre Vascular by 136.2% during the 3rd quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier's stock valued at $1,480,000 after acquiring an additional 9,750 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LMAT shares. Zacks Research lowered LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research report on Thursday, January 1st. Roth Mkm reissued a "buy" rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Wells Fargo & Company boosted their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an "equal weight" rating in a report on Thursday, February 26th. Weiss Ratings raised LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, March 10th. Finally, Citizens Jmp raised their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a "market outperform" rating in a report on Thursday, February 26th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of "Moderate Buy" and a consensus price target of $105.80.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $106.62 on Friday. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.07 and a beta of 0.66. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $115.33. The stock has a fifty day simple moving average of $96.94 and a 200 day simple moving average of $90.11.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the previous year, the business earned $0.49 EPS. The business's quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were paid a $0.25 dividend. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular's payout ratio is presently 39.84%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company's stock, valued at approximately $736,406.33. This represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 55,930 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the sale, the chief executive officer directly owned 1,476,500 shares of the company's stock, valued at $159,181,465. This represents a 3.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 215,438 shares of company stock worth $23,062,911 over the last ninety days. Insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.